Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 CHRNA4 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D08669 Varenicline [2] 6, 18
2 CHRNB2 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D08669 Varenicline [2] 6, 18
3 CSF3R [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03247 Lenograstim [7] 2, 13, 16, 18, 19, 57, 65
4 EPOR [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03231 Erythropoietin [10] 2, 6, 13, 18, 22, 46, 47, 70, 95, 96
5 MTOR [5] Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia D00753 Sirolimus [41] 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331
6 MTOR [5] Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia D02714 Everolimus [9] 34, 67, 89, 96, 137, 157, 158, 228, 277
7 MTOR [5] Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia D06068 Temsirolimus [4] 13, 34, 89, 331
8 GABBR1 [7] cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D00241 Baclofen [7] 2, 10, 13, 18, 65, 149, 206
9 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
10 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
11 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
12 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
13 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
14 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
15 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
16 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
17 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
18 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
19 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
20 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
21 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
22 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
23 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
24 GRIA1 [1] Spinocerebellar ataxia D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
25 GRIA1 [14] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
26 GRIA1 [1] Spinocerebellar ataxia D02696 Talampanel [2] 2, 6
27 GRIA1 [1] Spinocerebellar ataxia D08964 Perampanel [3] 2, 6, 144
28 GRIA2 [1] Spinocerebellar ataxia D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
29 GRIA2 [15] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
30 GRIA2 [1] Spinocerebellar ataxia D02696 Talampanel [2] 2, 6
31 GRIA2 [1] Spinocerebellar ataxia D08964 Perampanel [3] 2, 6, 144
32 GRIA3 [2] Spinocerebellar ataxia, Transcriptional misregulation in cancer D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
33 GRIA3 [13] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
34 GRIA3 [2] Spinocerebellar ataxia, Transcriptional misregulation in cancer D02696 Talampanel [2] 2, 6
35 GRIA3 [2] Spinocerebellar ataxia, Transcriptional misregulation in cancer D08964 Perampanel [3] 2, 6, 144
36 GRIA4 [10] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
37 GRIK1 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
38 GRIK2 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
39 GRIK3 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
40 GRIK4 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
41 GRIK5 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
42 GRIN1 [1] Spinocerebellar ataxia D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
43 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
44 GRIN1 [1] Spinocerebellar ataxia D00777 Amantadine [4] 6, 8, 13, 127
45 GRIN1 [1] Spinocerebellar ataxia D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
46 GRIN1 [1] Spinocerebellar ataxia D02780 Acamprosate [2] 6, 206
47 GRIN1 [1] Spinocerebellar ataxia D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
48 GRIN1 [1] Spinocerebellar ataxia D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
49 GRIN1 [1] Spinocerebellar ataxia D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
50 GRIN1 [1] Spinocerebellar ataxia D07058 Acamprosate [2] 6, 206
51 GRIN1 [1] Spinocerebellar ataxia D07283 Esketamine [3] 2, 4, 70
52 GRIN1 [1] Spinocerebellar ataxia D07441 Amantadine [4] 6, 8, 13, 127
53 GRIN1 [1] Spinocerebellar ataxia D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
54 GRIN1 [1] Spinocerebellar ataxia D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
55 GRIN1 [1] Spinocerebellar ataxia D09917 Latrepirdine [1] 8
56 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
57 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
58 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D00777 Amantadine [4] 6, 8, 13, 127
59 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
60 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D02780 Acamprosate [2] 6, 206
61 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
62 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
63 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
64 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
65 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
66 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
67 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
68 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
69 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
70 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
71 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
72 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D00777 Amantadine [4] 6, 8, 13, 127
73 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
74 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D02780 Acamprosate [2] 6, 206
75 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
76 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
77 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
78 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
79 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
80 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
81 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
82 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
83 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
84 GRIN2C [1] Spinocerebellar ataxia D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
85 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
86 GRIN2C [1] Spinocerebellar ataxia D00777 Amantadine [4] 6, 8, 13, 127
87 GRIN2C [1] Spinocerebellar ataxia D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
88 GRIN2C [1] Spinocerebellar ataxia D02780 Acamprosate [2] 6, 206
89 GRIN2C [1] Spinocerebellar ataxia D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
90 GRIN2C [1] Spinocerebellar ataxia D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
91 GRIN2C [1] Spinocerebellar ataxia D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
92 GRIN2C [1] Spinocerebellar ataxia D07058 Acamprosate [2] 6, 206
93 GRIN2C [1] Spinocerebellar ataxia D07283 Esketamine [3] 2, 4, 70
94 GRIN2C [1] Spinocerebellar ataxia D07441 Amantadine [4] 6, 8, 13, 127
95 GRIN2C [1] Spinocerebellar ataxia D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
96 GRIN2C [1] Spinocerebellar ataxia D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
97 GRIN2C [1] Spinocerebellar ataxia D09917 Latrepirdine [1] 8
98 GRIN2D [1] Spinocerebellar ataxia D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
99 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
100 GRIN2D [1] Spinocerebellar ataxia D00777 Amantadine [4] 6, 8, 13, 127
101 GRIN2D [1] Spinocerebellar ataxia D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
102 GRIN2D [1] Spinocerebellar ataxia D02780 Acamprosate [2] 6, 206
103 GRIN2D [1] Spinocerebellar ataxia D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
104 GRIN2D [1] Spinocerebellar ataxia D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
105 GRIN2D [1] Spinocerebellar ataxia D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
106 GRIN2D [1] Spinocerebellar ataxia D07058 Acamprosate [2] 6, 206
107 GRIN2D [1] Spinocerebellar ataxia D07283 Esketamine [3] 2, 4, 70
108 GRIN2D [1] Spinocerebellar ataxia D07441 Amantadine [4] 6, 8, 13, 127
109 GRIN2D [1] Spinocerebellar ataxia D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
110 GRIN2D [1] Spinocerebellar ataxia D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
111 GRIN2D [1] Spinocerebellar ataxia D09917 Latrepirdine [1] 8
112 NR3C1 [1] Neuroactive ligand-receptor interaction D00407 Methylprednisolone [43] 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
113 NR3C1 [1] Neuroactive ligand-receptor interaction D00751 Methylprednisolone [43] 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
114 NR3C1 [1] Neuroactive ligand-receptor interaction D00979 Methylprednisolone [43] 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
115 NR3C1 [1] Neuroactive ligand-receptor interaction D05000 Methylprednisolone [43] 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
116 NR3C1 [1] Neuroactive ligand-receptor interaction D05001 Methylprednisolone [43] 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
117 NR3C1 [1] Neuroactive ligand-receptor interaction D05002 Methylprednisolone [43] 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
118 HMGCR [4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D01915 Rosuvastatin [11] 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299
119 HMGCR [4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D08492 Rosuvastatin [11] 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299
120 IFNGR1 [18] Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
121 IFNGR2 [17] Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
122 KCNC3 [1] Spinocerebellar ataxia D04127 Dalfampridine [5] 3, 4, 6, 13, 14
123 KCNC3 [1] Spinocerebellar ataxia D10228 Amifampridine [3] 3, 11, 12
124 KCND3 [1] Spinocerebellar ataxia D00636 Amiodarone [2] 28, 127
125 KCND3 [1] Spinocerebellar ataxia D02910 Amiodarone [2] 28, 127
126 KCND3 [1] Spinocerebellar ataxia D04127 Dalfampridine [5] 3, 4, 6, 13, 14
127 KCND3 [1] Spinocerebellar ataxia D10228 Amifampridine [3] 3, 11, 12
128 MAP3K5 [4] Tight junction, TNF signaling pathway, Thermogenesis, Spinocerebellar ataxia D10988 Selonsertib [1] 86
129 NFE2L2 [7] Protein processing in endoplasmic reticulum, Parkinson disease, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10964 Omaveloxolone [1] 18
130 PIK3CA [9] VEGF signaling pathway, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Yersinia infection, Viral carcinogenesis D11158 Leniolisib [2] 53, 65
131 PIK3CB [9] VEGF signaling pathway, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Yersinia infection, Viral carcinogenesis D11158 Leniolisib [2] 53, 65
132 PIK3CD [9] VEGF signaling pathway, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Yersinia infection, Viral carcinogenesis D11158 Leniolisib [2] 53, 65
133 PIK3CD [9] VEGF signaling pathway, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Yersinia infection, Viral carcinogenesis D11437 Parsaclisib [3] 35, 53, 61
134 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
135 PSMB5 [1] Spinocerebellar ataxia D03150 Bortezomib [16] 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331
136 PSMB5 [1] Spinocerebellar ataxia D08880 Carfilzomib [1] 28
137 PSMB5 [1] Spinocerebellar ataxia D10130 Ixazomib [5] 13, 16, 28, 51, 61
138 SLC6A2 [1] Synaptic vesicle cycle D00817 Bupropion [4] 18, 21, 96, 171
139 SLC6A2 [1] Synaptic vesicle cycle D07591 Bupropion [4] 18, 21, 96, 171
140 SLC6A2 [1] Synaptic vesicle cycle D07938 Bupropion [4] 18, 21, 96, 171
141 SLC6A3 [7] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D00817 Bupropion [5] 8, 18, 21, 96, 171
142 SLC6A3 [7] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D07591 Bupropion [5] 8, 18, 21, 96, 171
143 SLC6A3 [7] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D07938 Bupropion [5] 8, 18, 21, 96, 171
144 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D00822 Citalopram [7] 6, 8, 13, 18, 46, 98, 127
145 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07704 Citalopram [7] 6, 8, 13, 18, 46, 98, 127
146 VDR [5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00129 Calcitriol [9] 18, 37, 46, 49, 66, 96, 158, 235, 326
147 GABBR2 [7] cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D00241 Baclofen [7] 2, 10, 13, 18, 65, 149, 206